MANTLE CELL LYMPHOMA

© 2009 Elsevier. All rights reserved. Mantle cell lymphoma (MCL) is a mature, aggressive B cell lymphoma that usually presents at an advanced stage, with frequent involvement of the peripheral blood (PB) [1,2]. MCL is the most common lymphoma presenting as multiple lymphomatous polyposis of the intestine [3–6]. The neoplastic cells of MCL express CD5, CD20 and CD43, but not CD23 or myeloid antigens [2,7]. In patients with a prior history of MCL, the appearance of leukemic cells usually heralds a relapse, particularly if the leukemic cells express antigens in common with the initial neoplastic cells. CD19 is a membrane protein expressed in B cell neoplasms and in a subset of acute myeloid leukemias (AMLs) [8–10] while CD43 is a leukocyte-specific surface molecule expressed in a variety of hematopoietic cells [11–13]. Received: Feb 6, 2009 Accepted: Apr 6, 2009 Address correspondence and reprint requests to: Dr Shih-Sung Chuang, Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan. E-mail: cmh5301@mail.chimei.org.tw ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA